<DOC>
	<DOC>NCT00646542</DOC>
	<brief_summary>This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) when used in patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal insufficiency.</brief_summary>
	<brief_title>Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>History T2DM Moderate or Severe Renal Impairment Glucose &gt; 270 mg/dL (&gt;15 mmol/L) Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Type 2 diabetes, vildagliptin</keyword>
</DOC>